<DOC>
	<DOCNO>NCT02047227</DOCNO>
	<brief_summary>This Phase 3 , randomize , control , single-blind , multicenter , parallel-arm trial ass safety efficacy Pergoveris® ( recombinant human follicle stimulate hormone [ r-hFSH ] /recombinant human luteinising hormone [ r-hLH ] ) GONAL-f® multifollicular development part assist reproductive technology ( ART ) treatment cycle poor ovarian responder , aligned 2011 Consensus Meeting European Society Human Reproduction Embryology ( ESHRE ) criterion .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety Pergoveris® Assisted Reproductive Technology ( ESPART )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Poor ovarian responder accord specific criterion align poor ovarian response ( POR ) criterion define 2011 Consensus Meeting European Society Human Reproduction Embryology ( ESHRE ) mention protocol Female subject , less ( &lt; ) 41 year age ( accord date birth time informed consent ) eligible ovarian stimulation ART treatment , include intracytoplasmic sperm injection ( ICSI ) Absence anatomical abnormality reproductive tract would interfere implantation pregnancy Absence medical condition pregnancy contraindicate Body mass index 18 30 kilogram per square meter ( kg/m^2 ) , inclusive Motile , ejaculatory sperm must available ( donate and/or cryopreserved sperm allow ) . Intracytoplasmic sperm injection allow trial Minimum 1 month without treatment either clomiphene citrate gonadotrophin prior screening Signed date informed consent indicate subject inform pertinent aspects trial prior enrollment Two episode POR maximal stimulation History presence tumor hypothalamus pituitary gland History presence ovarian enlargement cyst unknown etiology , presence ovarian cyst great 25 mm day randomization Presence endometriosis Grade III IV , confirm suspect Presence uni bilateral hydrosalpinx Abnormal gynecological bleeding undetermined origin Contraindication pregnant and/or carry pregnancy term History presence ovarian , uterine mammary cancer Use testicular epididymal sperm Other protocol define exclusion criterion could apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ESPART</keyword>
	<keyword>Reproductive Techniques , Assisted</keyword>
	<keyword>Infertility</keyword>
	<keyword>Pergoveris®</keyword>
	<keyword>GONAL-f®</keyword>
</DOC>